BCRP/ABCG2 Expression and Gefitinib Resistance in Lung Cancer
Author Information
Author(s): Chen Yun-Ju, Huang Wei-Chien, Wei Ya-Ling, Hsu Sheng-Chieh, Yuan Ping, Lin Heather Y., Wistuba Ignacio I., Lee J. Jack, Yen Chia-Jui, Su Wu-Chou, Chang Kwang-Yu, Chang Wen-Chang, Chou Tse-Chuan, Chou Chao-Kai, Tsai Chang-Hai, Hung Mien-Chie
Primary Institution: China Medical University Hospital
Hypothesis
Does elevated BCRP/ABCG2 expression confer acquired resistance to gefitinib in wild-type EGFR-expressing lung cancer cells?
Conclusion
BCRP/ABCG2 expression may predict poor efficacy of gefitinib treatment, and targeting it could improve treatment outcomes.
Supporting Evidence
- BCRP/ABCG2 expression was found to be elevated in gefitinib-resistant cancer cells.
- Co-treatment with BCRP/ABCG2 inhibitors improved the effectiveness of gefitinib.
- Patients with low BCRP/ABCG2 expression had better survival outcomes with gefitinib treatment.
Takeaway
Some lung cancer cells can resist a drug called gefitinib because they have a special protein that pumps the drug out of the cells. If we block that protein, the drug can work better.
Methodology
The study used cell lines and patient samples to analyze BCRP/ABCG2 expression and its correlation with gefitinib resistance.
Potential Biases
Potential biases may arise from the selection of cell lines and patient samples used in the study.
Limitations
The study's findings may not be generalizable to all lung cancer patients, as it focused on specific cell lines and a limited patient population.
Participant Demographics
The study included lung cancer patients, with a focus on those expressing wild-type EGFR.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website